论文部分内容阅读
美国国立癌症研究所(NCI)癌症治疗部(DCT)自1975年起采用一种新的预见性筛选程序。但由于无胸腺小鼠的供应量以及维持动物健康的有关后勤等问题,开始工作进展得很缓慢。近来,对此程序集中了力量新药抗肿瘤试验得以顺利进行。对照新筛选系统初期提出的问题,回顾一下结果是很有意义的。DCT筛选药物的流程见图1肿瘤谱系列于表一。广义说,抗肿瘤药物筛选程序的基本目的是为临床肿瘤治疗提供新的更有效的药物。包括增加真阳性化合物(即筛选有活性,临床也有活性)的检出数;降低假阳性数(即
The National Cancer Institute (NCI) Cancer Treatment Unit (DCT) has adopted a new predictive screening program since 1975. However, due to the availability of athymic mice and the logistical issues related to the maintenance of animal health, the work started slowly. Recently, the program focused on the power of new anti-tumor drugs to be carried out smoothly. It is instructive to review the results against the initial questions posed by the new screening system. DCT screening drug process shown in Figure 1 tumor spectrum series in Table 1. Broadly speaking, the basic purpose of the anti-cancer drug screening program is to provide new and more effective drugs for the treatment of clinical oncology. Including increasing the number of true-positive compounds (ie screening for activity, clinical activity); reducing the number of false-positives (ie